An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

par Jerod L. Ptacin, Carolina E. Caffaro, Lina Ma, Kristine M. San Jose Gall, Hans R. Aerni, Nicole V. Acuff, Rob W. Herman, Yelena Pavlova, Michael J. Pena, David B. Chen, Lilia K. Koriazova, Laura K. Shawver, Ingrid B. Joseph, Marcos E. Milla
Publié 2021